{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1362825893545559808.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1007/s40263-015-0249-8"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s40263-015-0249-8.pdf"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/article/10.1007/s40263-015-0249-8/fulltext.html"}},{"identifier":{"@type":"URI","@value":"http://link.springer.com/content/pdf/10.1007/s40263-015-0249-8"}}],"dc:title":[{"@value":"Defining the Role of the Monoamine Oxidase-B Inhibitors for Parkinson’s Disease"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1382825893545559808","@type":"Researcher","foaf:name":[{"@value":"Daphne Robakis"}]},{"@id":"https://cir.nii.ac.jp/crid/1382825893545559809","@type":"Researcher","foaf:name":[{"@value":"Stanley Fahn"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"11727047"},{"@type":"EISSN","@value":"11791934"}],"prism:publicationName":[{"@value":"CNS Drugs"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2015-06","prism:volume":"29","prism:number":"6","prism:startingPage":"433","prism:endingPage":"441"},"reviewed":"false","dc:rights":["http://www.springer.com/tdm"],"url":[{"@id":"http://link.springer.com/content/pdf/10.1007/s40263-015-0249-8.pdf"},{"@id":"http://link.springer.com/article/10.1007/s40263-015-0249-8/fulltext.html"},{"@id":"http://link.springer.com/content/pdf/10.1007/s40263-015-0249-8"}],"createdAt":"2015-07-11","modifiedAt":"2024-06-09","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360285706248491648","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-term, open-label, phase 3 study of rasagiline in Japanese patients with early Parkinson’s disease"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576966732978688","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Monoamine Oxidase Inhibitor (MAO-I)-Mediated Neuroprotection for Treating Parkinson’s Disease"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1007/s40263-015-0249-8"},{"@type":"CROSSREF","@value":"10.1007/s00702-018-1964-3_references_DOI_Hjd1DKEE9RBcWUlWhBSNjoEAa2r"},{"@type":"CROSSREF","@value":"10.1007/978-3-319-56015-1_238-1_references_DOI_Hjd1DKEE9RBcWUlWhBSNjoEAa2r"}]}